

Making Personalized Medicine A Reality



IBA MOLECULAR
INVESTS IN THE FUTURE

ENSURING QUALITY
IN EVERY PART OF
A PET IMAGING
PROGRAM


PROVIDING INNOVATIVE,
INFORMATIVE ONLINE
SESSIONS FOR PET
PROFESSIONALS

STREAMLINING EVERY
ASPECT OF THE
DIAGNOSTIC IMAGING
PRACTICE

IBA Molecular

INVESTS IN THE FUTURE

Network transformation puts IBA in the forefront of radiopharmaceutical manufacturing

READ MORE INSIDE 

IBA Molecular Invests in the Future of Personalized Medicine

As part of its long term plan toward making “Personalized Medicine” a reality, IBA Molecular is investing over \$100 million to transform the company worldwide. Always an industry leader and innovator, IBA is now taking a leading role in propelling nuclear medicine and molecular imaging into the future, with the promise of broader use and impact on the diagnosis and care of patients around the world.

In North America, this investment can be seen in the upgrade of the IBA network of radiopharmacies, preparing them for the manufacture and distribution of new, targeted radiotracers currently in development. Redesigned facilities, new equipment and innovative procedures will enable the company to enhance its role as a preferred partner in the production and delivery of molecular imaging products. IBA and its strategic partners, including Willex, Aposense and Bayer, are already deeply involved in the research and development of molecular tracers across a broad range of disease indications.

As part of this process, IBA Molecular is working with the U.S. Food and Drug Administration (FDA) to register its PET drug production facilities and file abbreviated new drug applications (ANDAs) as part of regulations currently being put in place. This continues IBA’s longstanding adherence to all FDA and US Pharmacopeia standards for radiopharmaceutical production. However, this particular upgrade will put in place procedures and standards more stringent than the FDA initiatives, as we meet the requirements of our pharmaceutical development partners.

Key to the successful completion of these innovations has been the dedicated work of the outstanding group of pharmacists, engineers, technicians, QA and QP specialists and support staff at IBA. Beyond their expertise and experience, they are dedicated to the Mission of the company, which is to “Protect, Enhance and Save Lives.”

This network transformation will create a flexible manufacturing platform, allowing IBA to deliver on the promise of innovative diagnostic and therapeutic molecular products. These products will provide physicians with the tools they need to make accurate and timely diagnoses, deliver targeted therapies, measure treatment effectiveness, and provide the best possible care and outcome for the patient.



Sterling, Virginia Pharmacy (Q1 2011)



Kansas City, Missouri Pharmacy (Q2 2011)

Ensuring Quality in Every Part of a PET Imaging Program

IBA Molecular is committed to the pursuit of excellence in every facet of molecular imaging. This starts with the production and distribution of quality radiopharmaceuticals to support PET imaging programs nationwide. Equally important are the company’s efforts to support those programs, providing the tools, resources and expert professionals that can help PET sites achieve their goals through the development of quality improvement and assurance initiatives.

Practice Excellence is a quality development program which IBA has introduced for select PET imaging programs. It focuses on identifying key areas in the imaging enterprise where improved quality can make a significant difference. It begins at the imaging site, where the PET technologists and physicians work together to refine PET scan protocols and procedures to ensure the best quality images and reports. IBA offers onsite and online resources to assist, including tutorials on patient preparation, scan protocols for specific indications and stages, Peer Review services